Eporgen is the first Italian company, entirely funded by private, non-institutional investors, which is dedicated to seed capital investments in the area of life sciences.

Eporgenā­Šssion is to identify and select innovative projects in the area of life sciences, in which it invests in order to create a balanced portfolio of small start-up companies that are supported in their management and controlled by Eporgen. These start-up companies are built around intellectual property that is being developed up to a proof-of-concept stage and subsequently licensed out to suitable partners, to generate new economic resources.

The current portfolio of Eporgen is constituted of eleven start-up companies, with innovative early stage therapeutics and diagnostics that cover diverse disease areas (oncology, anti-infectives, cardiovascular), approaches (small molecules, proteins, peptides, vaccines) and technology applications!